Amyris Contracted by BioMaP Consortium to Strengthen U.S. Medicine Supply

• Amyris has been awarded $12.3 million from the U.S. government to advance pharmaceutical manufacturing of FDA-shortlisted drugs.

• The funding will support the development of up to three small molecule drugs over the next two years.

Amyris, a synthetic biology and industrial biotechnology company, has secured a $12.3 million agreement through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-C) from the Administration for Strategic Preparedness and Response’s (ASPR) Center for Industrial Base Management and Supply Chain (IBMSC). The funding will be used to advance pharmaceutical manufacturing in the U.S. by developing up to three small molecule drugs currently on the FDA’s drug shortage list.

Over the next two years, Amyris will leverage its expertise in organism engineering, precision fermentation, and synthetic chemistry to achieve technology development milestones. Based on these advancements, IBMSC and Amyris will decide which drug targets to move forward for sample production. The company will also seek partnerships with GMP-manufacturing firms to bring these drugs to market.

“Amyris has consistently pushed the boundaries of what is possible in industrial biotechnology,” said Kathy Fortmann, CEO of Amyris. She added that the new funding will accelerate the company’s R&D efforts to deliver active pharmaceutical ingredients, addressing key gaps in the U.S. supply chain.

This project is funded by the U.S. Department of Health and Human Services under an agreement with the IBMSC. Amyris’ work is part of a broader effort to enhance U.S. pharmaceutical manufacturing capabilities and address critical supply chain vulnerabilities.